Breakthrough in ulcerative colitis treatment? Microbiotica unveils MB310 data
Microbiotica, a clinical-stage biopharmaceutical company pioneering microbiome-based therapy, has presented significant new data on MB310, its investigational treatment for ulcerative colitis, at two prominent medical ... Read More
Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical are making significant strides in the development of BH3120, a next-generation cancer immunotherapy. Updates on the innovative treatment were ... Read More
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More